Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
doxorubicin medac innrennslislyf, lausn 2 mg/ml
medac gesellschaft für klinische spezialpräparate gmbh - doxorubicinum hýdróklóríð - innrennslislyf, lausn - 2 mg/ml
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
bcg-medac duft og leysir fyrir þvagblöðrudreifu
medac gesellschaft für klinische spezialpräparate gmbh - bcg bacteria - duft og leysir fyrir þvagblöðrudreifu
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
hydroxyurea medac hart hylki 500 mg
medac gesellschaft für klinische spezialpräparate gmbh - hydroxycarbamidum inn - hart hylki - 500 mg
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
carmustine medac (previously carmustine obvius)
medac gesellschaft für klinische spezialpräparate mbh - carmustine - hodgkin disease; lymphoma, non-hodgkin - Æxlishemjandi lyf - carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery): , brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, secondary therapy in non-hodgkin’s lymphoma and hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (hpct) in malignant haematological diseases (hodgkin’s disease / non-hodgkin’s lymphoma).
Ísland -
íslenska -
LYFJASTOFNUN (Icelandic Medicines Agency)
bendamustine medac stofn fyrir innrennslisþykkni, lausn 2,5 mg/ml
medac gesellschaft für klinische spezialpräparate gmbh - bendamustinum hýdróklóríð - stofn fyrir innrennslisþykkni, lausn - 2,5 mg/ml
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
mycapssa
amryt pharmaceuticals dac - octreotide acetate - acromegaly - hinsveiflur og heilahimnubólur og hliðstæður - mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
atectura breezhaler
novartis europharm limited - indacaterol acetate, mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - astma - lyf til veikindi öndunarvegi sjúkdómum, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - lyf til veikindi öndunarvegi sjúkdómum, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
Evrópusambandið -
íslenska -
EMA (European Medicines Agency)
hirobriz breezhaler
novartis europharm limited - indacaterol maleat - lungnasjúkdómur, langvarandi hindrandi - lyf til veikindi öndunarvegi sjúkdómum, - hirobriz breezhaler er ætlað til meðhöndlunar berkjuvíkkandi meðferð á loftflæði hindrun hjá fullorðnum sjúklingum með langvinna lungnateppu.